News Details - novonordisk.com
Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk takes a hit as CagriSema underperforms in weight …
Dec 20, 2024 · Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations sending the company’s stock price spiralling.
Novo Nordisk’s next-generation weight-loss drug CagriSema …
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...
Novo Nordisk's CagriSema Shows Superior, But Lower-than …
Dec 20, 2024 · (RTTNews) - Novo Nordisk A/S (NVO) announced Friday that its experimental obesity drug CagriSema demonstrated superior weight loss in adults with obesity or overweight in the REDEFINE 1 phase 3...
Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)
2 days ago · A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the drug than previously predicted.. The Danish company and two executives allegedly expressed confidence CagriSema would cause 25% weight loss on average, but failed to disclose patients could modify ...
Novo Nosedives on Underwhelming CagriSema Phase III Weight …
Dec 20, 2024 · Novo Nordisk on Friday released headline data from the Phase III REDEFINE 1 trial of its next-generation weight-loss therapy CagriSema, touting “superior weight loss” in people with obesity and overweight than just cagrilintide, semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes) or placebo.. CagriSema’s performance fell short of Novo’s prior projections for its ...
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · In a statement, Novo said that the drug, a combination therapy called cagrisema, helped people lose up to about 23% of their body weight after 68 weeks, about 20 percentage points higher than placebo recipients and 7 higher than those who received the company’s popular weight loss drug Wegovy alone.
Novo Nordisk: Cagrisema shows ‘superior’ weight loss in …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema — a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg — compared to the individual...